Future Impact of mRNA Therapy on Cardiovascular Diseases
The silver lining of the recent pandemic was that it accelerated the emergence of messenger ribonucleic acid (mRNA) therapeutics. The great promise of mRNA therapeutics was highlighted by the speed at which the vaccines were created, tested, and proven to be relatively safe and highly effective. The...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Houston Methodist DeBakey Heart & Vascular Center
2022-12-01
|
| Series: | Methodist DeBakey Cardiovascular Journal |
| Subjects: | |
| Online Access: | https://account.journal.houstonmethodist.org/index.php/up-j-mdbcj/article/view/1169 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849468525301727232 |
|---|---|
| author | John P. Cooke Keith A. Youker |
| author_facet | John P. Cooke Keith A. Youker |
| author_sort | John P. Cooke |
| collection | DOAJ |
| description | The silver lining of the recent pandemic was that it accelerated the emergence of messenger ribonucleic acid (mRNA) therapeutics. The great promise of mRNA therapeutics was highlighted by the speed at which the vaccines were created, tested, and proven to be relatively safe and highly effective. There are a wide variety of mRNA therapeutics now under development, and dozens of these are in clinical trials. These therapeutics are generating a major paradigm shift in medical therapy, including the treatment of cardiovascular disease. Most of the cardiovascular mRNA therapies are still in preclinical development, although a phase 2a trial of mRNA therapy for myocardial ischemia has been completed with promising results.1 The application of mRNA therapies to cardiovascular diseases is virtually limitless, and ongoing work includes mRNA therapies for myocardial ischemia, heart failure, arrhythmias, hypercholesterolemia, and arterial occlusive diseases. In addition, mRNA may be used to enhance cell therapies. In the future, mRNA therapies for cardiovascular disease are destined to supplant some of our current biologics and pharmacotherapies and will be used to treat previously untreatable cardiovascular diseases. Furthermore, mRNA therapies can be personalized, and they can be rapidly generated in current Good Manufacturing Practice facilities with a modest footprint, facilitating the rise of hospital-based regional centers of RNA therapeutics. |
| format | Article |
| id | doaj-art-0980d9e39cb04d509595ea92f3cde82c |
| institution | Kabale University |
| issn | 1947-6108 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | Houston Methodist DeBakey Heart & Vascular Center |
| record_format | Article |
| series | Methodist DeBakey Cardiovascular Journal |
| spelling | doaj-art-0980d9e39cb04d509595ea92f3cde82c2025-08-20T03:25:50ZengHouston Methodist DeBakey Heart & Vascular CenterMethodist DeBakey Cardiovascular Journal1947-61082022-12-01185647310.14797/mdcvj.11691146Future Impact of mRNA Therapy on Cardiovascular DiseasesJohn P. Cooke0https://orcid.org/0000-0003-0033-9138Keith A. Youker1https://orcid.org/0000-0003-2535-7973Houston Methodist Research Institute, Houston, TexasHouston Methodist Research Institute, Houston, TexasThe silver lining of the recent pandemic was that it accelerated the emergence of messenger ribonucleic acid (mRNA) therapeutics. The great promise of mRNA therapeutics was highlighted by the speed at which the vaccines were created, tested, and proven to be relatively safe and highly effective. There are a wide variety of mRNA therapeutics now under development, and dozens of these are in clinical trials. These therapeutics are generating a major paradigm shift in medical therapy, including the treatment of cardiovascular disease. Most of the cardiovascular mRNA therapies are still in preclinical development, although a phase 2a trial of mRNA therapy for myocardial ischemia has been completed with promising results.1 The application of mRNA therapies to cardiovascular diseases is virtually limitless, and ongoing work includes mRNA therapies for myocardial ischemia, heart failure, arrhythmias, hypercholesterolemia, and arterial occlusive diseases. In addition, mRNA may be used to enhance cell therapies. In the future, mRNA therapies for cardiovascular disease are destined to supplant some of our current biologics and pharmacotherapies and will be used to treat previously untreatable cardiovascular diseases. Furthermore, mRNA therapies can be personalized, and they can be rapidly generated in current Good Manufacturing Practice facilities with a modest footprint, facilitating the rise of hospital-based regional centers of RNA therapeutics.https://account.journal.houstonmethodist.org/index.php/up-j-mdbcj/article/view/1169myocardial infarctionheart failurearrhythmiashypercholesterolemiasenescencetelomerasevaccine |
| spellingShingle | John P. Cooke Keith A. Youker Future Impact of mRNA Therapy on Cardiovascular Diseases Methodist DeBakey Cardiovascular Journal myocardial infarction heart failure arrhythmias hypercholesterolemia senescence telomerase vaccine |
| title | Future Impact of mRNA Therapy on Cardiovascular Diseases |
| title_full | Future Impact of mRNA Therapy on Cardiovascular Diseases |
| title_fullStr | Future Impact of mRNA Therapy on Cardiovascular Diseases |
| title_full_unstemmed | Future Impact of mRNA Therapy on Cardiovascular Diseases |
| title_short | Future Impact of mRNA Therapy on Cardiovascular Diseases |
| title_sort | future impact of mrna therapy on cardiovascular diseases |
| topic | myocardial infarction heart failure arrhythmias hypercholesterolemia senescence telomerase vaccine |
| url | https://account.journal.houstonmethodist.org/index.php/up-j-mdbcj/article/view/1169 |
| work_keys_str_mv | AT johnpcooke futureimpactofmrnatherapyoncardiovasculardiseases AT keithayouker futureimpactofmrnatherapyoncardiovasculardiseases |